Survey on the Knowledge and Management of Cancer-Associated Thrombosis (CAT) in Haemato-Oncology Patients with Thrombocytopenia among Haematologists and Haematology Residents in Nigeria.

BACKGROUND: Arterial or venous thrombosis can complicate cancer, and 20% of cancer patients may develop venous thromboembolic disorders. Venous thromboembolism (VTE) is common in some haematologic malignancies and may coexist with thrombocytopenia in those haematologic malignancies. We carried out this survey to assess the knowledge and practice of haematologists and resident doctors in haematology in Nigeria regarding the management of thrombocytopenia and cancer-associated thrombosis. METHODS: This was a survey that was shared electronically with participants who were consultant haematologists and resident doctors in haematology in Nigeria.. RESULTS: There were 106 respondents, 70 (66%) of which were consultant haematologists. About a third (30.2%) of the respondents saw 6-10 patients with blood malignancies monthly. Fifty-seven (53.8%) of the respondents carried out risk assessment in their patients for cancer-associated thrombosis (CAT); 63 (59.4%) of the respondents saw 1-2 cancer patients with thrombosis in 3 months. The most common mode of treatment was pharmacological - 94 (88%) respondents used low molecular weight heparin. The most common haematologic malignancies associated with thrombocytopenia were acute leukaemias (69; 67%). The most common decision taken by respondents was to stop anticoagulants and transfuse platelets because the most frequent concern was the risk of bleeding in this group of patients. CONCLUSION: Many haematologists and haematology residents had a high level of awareness, knowledge and good practice regarding thrombocytopenia with CAT in haematooncology patients; however, there is a need for improved knowledge and unified protocols for treatment in line with newer management guidelines.

CONTEXTE: La thrombose artérielle ou veineuse peut compliquer le cancer, et 20 % des patients cancéreux peuvent présenter des troubles thromboemboliques veineux. La thromboembolie veineuse (TEV) est fréquente dans certaines hémopathies malignes et peut coexister avec une thrombocytopénie dans ces hémopathies malignes. Nous avons mené cette enquête pour évaluer les connaissances et la pratique des hématologues et des médecins résidents en hématologie au Nigeria concernant la gestion de la thrombocytopénie et de la thrombose associée au cancer. MÉTHODES: Il s'agit d'une enquête qui a été partagée électroniquement avec les participants qui sont des hématologues consultants et des médecins résidents en hématologie au Nigéria. RÉSULTATS: 106 personnes ont répondu à l'enquête, dont 70 (66%) étaient des hématologues consultants. Environ un tiers (30,2 %) des personnes interrogées voyaient chaque mois 6 à 10 patients atteints de tumeurs hématologiques malignes. Cinquante-sept (53,8 %) des personnes interrogées ont procédé à une évaluation du risque de thrombose associée au cancer chez leurs patients ; 63 (59,4 %) des personnes interrogées ont vu 1 à 2 patients cancéreux atteints de thrombose en 3 mois. Le mode de traitement le plus courant était pharmacologique - 94 (88%) des personnes interrogées utilisaient de l'héparine de faible poids moléculaire. Les hémopathies malignes les plus fréquemment associées à la thrombocytopénie étaient les leucémies aiguës (69 ; 67%). La décision la plus fréquente prise par les personnes interrogées était d'arrêter les anticoagulants et de transfuser des plaquettes parce que la préoccupation la plus fréquente était le risque de saignement dans ce groupe de patients. CONCLUSION: De nombreux hématologues et résidents en hématologie avaient un niveau élevé de sensibilisation, de connaissances et de bonnes pratiques concernant la thrombocytopénie avec CAT chez les patients hémato-oncologiques; cependant, il est nécessaire d'améliorer les connaissances et d'unifier les protocoles de traitement conformément aux nouvelles directives de prise en charge. Mots clés: Thrombose associée au cancer, Hémato-oncologie, Thrombocytopénie, Hemorragie, Thrombose.

Evaluation of Obstetricians' Opinion of Thrombocytopenia in Pregnancy: A Cross-Sectional Study.

BACKGROUND: Thrombocytopenia occurs in about 8-10% of pregnancies. Thrombocytopenia may be incidental in pregnancy and could point to medical or gestational conditions that may pose a morbidity and mortality risk to both mother and foetus. AIM: To determine Obstetricians' view/opinion about thrombocytopenia in pregnancy. METHODS: A pre-tested structured questionnaire was distributed amongst consultant and resident obstetricians during their antenatal clinics in 3 tertiary hospitals over a period of one month. Analysis was descriptive and results were expressed as frequencies in words, tables and charts. RESULTS: A total of 91 responders were studied of which 24 were consultants (26.4%), 57 (62.6%) senior registrars and 10 (11%) were registrars. There were 20 (22.7%) responders who were unaware of incidental thrombocytopenia in pregnancy. Most obstetricians (n=83, 91.2%) requested for only packed cell volume (PCV) at antenatal booking, only 2 (2.9%) routinely requested for full blood count (FBC). At booking; only 10 (11.1%) obstetricians asked for a history of thrombocytopenia. Majority (n=87, 98.9%) never requested for platelet counts. If they encountered thrombocytopenia, up to 89 (97.8%) would investigate further with a repeat FBC (n=77, 86.5%), coagulation screen (n=54, 61.4%) or bone marrow aspiration (n=20, 24.7%). Most of the obstetricians (n=82, 96.5%) would transfuse patients with thrombocytopenia and 34 (43.6%) of them would do so when the count is <50 X 109/L. CONCLUSION: Obstetricians have the capacity to investigate symptomatic thrombocytopenia in pregnancy but do not routinely screen for asymptomatic thrombocytopenia. Routine FBC if done at booking may identify missed cases of asymptomatic thrombo-cytopenia for adequate management.

CONTEXTE: La thrombocytopénie survient dans environ 8 à 10 % des grossesses. La thrombocytopénie peut être fortuite pendant la grossesse et peut indiquer une condition médicale ou gestationnelle qui peuvent poser un risque de morbidité et de mortalité pour la mère et le fœtus. OBJECTIF: Déterminer le point de vue/opinion des obstétriciens concernant la thrombocytopénie pendant la grossesse. MÉTHODES: Un questionnaire structuré et pré-testé a été distribué parmi les obstétriciens consultants et résidents lors de leurs consultations prénatales dans trois hôpitaux tertiaires sur une période d'un mois. L'analyse descriptive et les résultats ont été exprimés sous forme de fréquences en mots, tableaux et graphiques. RÉSULTATS: Au total, 91 répondants ont été étudiés, dont 24 étaient Les conseillers(26,4 %), 57 (62,6 %) des chefs de clinique et 10 (11 %) des titulaires. Il y' avait Vingt (22,7 %) des répondants n'étaient pas au courant de la présence de thrombocytopénie fortuite pendant la grossesse. La plupart des obstétriciens (n=83, 91,2 %) demandaient uniquement un volume globulaire (VGP) lors de la consultation anténatale, seuls 2 (2,9 %) demandaient systématiquement une formule sanguine complète (FBC). Lors de la réservation, seuls 10 obstétriciens (11,1 %) ont demandé des antécédents de thrombocytopénie. La majorité (n=87, 98,9 %) n'a jamais demandé de numération plaquettaire. S'ils rencontraient une thrombocytopénie, jusqu'à 89 (97,8 %) poursuivaient les investigations en répétant la numération formule sanguine (n=77, 86,5%), un test de coagulation (n=54, 61,4%) ou une ponction de moelle osseuse (n=20, 24.7%). La plupart des obstétriciens (n=82, 96,5 %) transfuseraient des patients atteints de thrombocytopénie et 34 (43,6%) d'entre eux le feraient lorsque la numération est <50 X 109/L. CONCLUSION: Les obstétriciens ont la capacité d'investiguer la thrombopénie symptomatique pendant la grossesse, mais ne procèdent pas systématiquement au dépistage systématique de la thrombocytopénie asymptomatique. La FBC de routine, si elle est effectuée peut identifier les cas manqués de thrombocytopénie asymptomatique pour une prise en charge adéquate. Mots clés: Thrombocytopénie, grossesse, obstétriciens.

ABO blood group as a biomarker of preeclampsia among antenatal clinic attendees in Nigeria.

BACKGROUND: The clinical application of the ABO blood group is not limited to transfusion medicine but extends to other aspects of medicine. Its impact on preeclampsia is controversial. AIM: To determine the association of ABO blood group type with preeclampsia. SUBJECTS AND METHODS: This was a cross-sectional analytical study of 66 women with preeclampsia and 81 apparently healthy women controls carried out in a tertiary health institution. The case and control groups were consecutively recruited during antenatal clinic visits and matched for age, parity, and gestational age. Data on demographics and the ABO blood group of the two groups of individuals were obtained. The analysis was both descriptive and inferential using the statistical package for social sciences (SPSS) version 21 (Chicago Il, USA). A P value of <0.05 was considered statistically significant. RESULTS: The mean age of the participants was 30.6 (4.9), 95% CI: 27.76-33.95. The majority of the women were ≤40 years (98.5%) and multigravidae constituted 81.8%. Forty-six (69.7%) women with preeclampsia had blood group O and 20 (30.3%) had a non-O blood group. Forty-nine (60.5%) of the controls had blood group O and 32 (39.5%) had a non-O blood group. The observed difference was not statistically significant (OR 1.50; 95% CI: 0.75-3.0; P = 0.26). The odds ratio for developing preeclampsia was 0.83 (95% CI: 0.37-1.91; P = 0.67) for the primigravidae. The non-O blood groups were more likely to present with symptoms than the O group (P < 0.01). Twenty-six (39.4%) women with preeclampsia had a mild disease while 40 (60.6%) had severe disease. CONCLUSION: Women with non-O blood groups are not at increased risk of developing preeclampsia but are more likely to be symptomatic than the O group.

Evaluation of laboratory investigative methods of diagnosing clonal hematological disorders in a resource-poor setting.

BACKGROUND: The successful treatment of patients with clonal hematological disorders (CHDs) depends largely on making an accurate diagnosis, which is, in turn, is dependent on performing specific diagnostic tests that are necessary. OBJECTIVES: This study assessed the laboratory investigative methods of diagnosing CHDs with regard to the specific required tests (SRTs) that were needed to make a final diagnosis in a center with limited resources. METHODS: This is a descriptive hospital-based retrospective study. For the study, data about laboratory investigation details of adults diagnosed with CHDs from 1995 to 2015 were retrieved. The SRTs were determined and data analyzed using SPSS version 20. RESULTS: A total of 129 case notes of adults in the age range of 18-80 years, diagnosed with CHDs, were used. Out of the 671 SRTs needed for diagnosis, only 304 (45.3%) were conducted. When an SRT was requested to be done within the treatment facility, the patients were significantly more likely to do it in comparison with when they were requested to get it done from an external referral laboratory. All the patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) had all (100%) their SRTs done while patients with non-Hodgkin's lymphoma (NHL) had the least (15.3%) of their SRTs done. Full blood count (FBC) was the most frequently used (n = 129; 100%) SRT for diagnosis while immunophenotyping (IMPT) was the least (n = 4; 8.3%) used SRT. CONCLUSION: Most of our patients had CHD diagnosis without the complete SRT, and this may cast doubt on the accuracy of diagnosis. Therefore, there is a crucial need for availability of more comprehensive laboratory services, especially in government-owned hospitals.

The economic burden of malignant and premalignant hematological diseases in Southern Nigeria.

BACKGROUND: Hematological malignancies are a significant cause of morbidity and mortality. They constitute an economic burden for the patients, their relatives, and the society because of the cost associated with their management, which is usually long term. We aimed to determine the total direct cost of managing patients with premalignant hematological disorders (PMHDs) and malignant hematological disorders (MHDs). MATERIALS AND METHODS: A hospital-based retrospective study was carried out between 1997 and 2015. Data were retrieved from the case notes of adult patients diagnosed with either PMHD or MHD. The total cost of medical care was calculated as the sum of in-patient and out-patient direct cost associated with their management. Data were analyzed using Statistical Package for Social Sciences. RESULTS: There was a total of 129 patients; 74 (57.4%) males and 55 (42.6%) females with mean age of 45.7 ± 16.3 years and the majority (n = 76, 58.9%) being employed. Males were more affected than the females except in chronic lymphocytic leukemia, myelodysplastic syndrome, and paroxysmal nocturnal hemoglobinuria. The commonest MHD was chronic myeloid leukemia with 37 (28.7%) patients. Full blood count was the commonest investigation done, whereas free light chains were the least (n = 2; 1.6%). The total cost of care for the 129 patients was N30,041,900.00 ($82,306.58) with an average total cost of care per patient of N232,882.95 ($638.04). Patients with non-Hodgkin lymphoma had the highest mean cost of care per patient (N373,196.30; $1,022.46). The average monthly expenditure per patient was about N70,000 ($190). CONCLUSION: In our setting, management of CHDs constitutes an economic burden.

Pattern of blood donation and characteristics of blood donors in Enugu, Southeast Nigeria.

BACKGROUND: Despite increasing need for blood donation in medical practice, little is known about pattern of blood donation and characteristics of blood donors in some African populations like Nigeria. This information is necessary in designing strategies and policies for improving blood transfusion services in Africa. AIM: The aim of this study is to determine the pattern of blood donation and characteristics of blood donors in Enugu, Southeast, Nigeria. MATERIALS AND METHODS: A cross-sectional study of 3377 blood donors at a tertiary hospital in Enugu, Nigeria from May 1, 2016 to April 30, 2017. Information sought included donors' sociodemographic characteristics; type of blood donor: Voluntary nonremunerated donor (VNRD), family replacement donor (FRD), or paid donor (PD); willingness to become VNRD in the future after counseling and education (at point of entry to blood bank) on its benefits to clinical practice; hemoglobin (Hb) level; and transfusion transmissible infections (TTIs). RESULTS: Mean age of blood donors was 28.8 ± 8.5 years, majority were male (3011, 89.2%) and students (1289, 32.8%). FRDs were the highest in number (1998, 59.2%), followed by PDs (746, 22.1%) and finally VNRDs (633, 18.7%). Of the 3377 persons that came for blood donation, 2537 (75.1%) were found eligible to donate while 840 (24.9%) were deferred on account of low Hb (602/3377, 17.8%) or positive infectious screening test (238/3377, 7.0%). The odds of a male donor being a VNRD were about one and half times that of a female donor (582/3011 [19.3%] vs. 51/366 [13.9%]; odds ratio: 1.48; 95% confidence interval: 1.09-2.02; P = 0.01). After counseling of FRDs and PDs, majority (54.3%) were willing to become VNRDs in the future. Donors' age >30 years, being of male sex, having tertiary level of education, and being employed were strongly associated with willingness to become VNRDs in the future (P < 0.001). CONCLUSION: VNRD made up <20% of the total number of donors in Enugu, Nigeria. There is a need for improvement in public enlightenment on the need for VNRDs and employment opportunities of the populace to improve voluntary blood donation.

Challenges in the management of bleeding disorders in Nigeria.

BACKGROUND: Bleeding disorders (BDs) are characterized by abnormal bleeding for which effective management requires a combination of skill, workforce, diagnostic facilities, and adequate therapeutic options. OBJECTIVES: The objectives of this study were to determine the capacity of Nigerian hematologists to handle BDs and to assess availability of required infrastructure, equipment, and treatment options. MATERIALS AND METHODS: This descriptive study was conducted during the 2016 scientific conference of the Nigerian Society for Hemetology and Blood Transfusion. A structured questionnaire was distributed to hematologists in attendance. Data were analyzed with SPSS version 21. RESULTS: A total of 55 (76.4%) hematologists from 27 centers responded. The most frequently carried out tests to assess bleeding were hemoglobin or packed cell volume (100%), full blood count (96.3%), and prothrombin time/international normalized ratio and activated partial thromboplastin time (77%). Many centers did not have a coagulometer (47.8%) or cold centrifuge (43.4%) and none had thromboelastography or rotational thromboelastometry. Fresh whole blood was the most accessible (88.5%) and up to one-third of the centers did not have access to component therapy. Only 39.1% centers had factor concentrates available. CONCLUSION: Facilities required for diagnosing and treating BD are significantly deficient in most centers in Nigeria. Funding to provide facility and training is required to improve on this inadequacy.